UNeMed Hosts Professionals From Japanese Companies

Comments Off on UNeMed Hosts Professionals From Japanese Companies Blog

by Agnes Lenagh, UNeMed | Feb. 22, 2013

One of the perks of working at UNeMed is the ability to interact with industry professionals worldwide. We’re always looking for new opportunities to engage companies and establish new friendships with industry personnel.

Such an opportunity arrived earlier this month when UNeMed President and CEO Michael Dixon, PhD, received a request from the International Professional Development (IPD) program manager at the University of Nebraska-Omaha: Japanese professionals interested in biotech, Takehide Kimura and Tatsuke Toya, wished to visit our facilities and discuss technology transfer at the University of Nebraska Medical Center (UNMC).

IPD prepares international professionals to be effective and successful in the world of global business. Companies around the world have participated in IPD since 1989 and enjoyed gaining authority in the global marketplace. The program includes intensive training in English language and communication skills, as well as knowledge of global business practices.

IPD also offers professionals an opportunity to develop their networks and access Omaha’s international business community. To achieve this, part of the program includes corporate visits where trainees spend about four hours interacting with staff and touring facilities. This is where UNeMed comes in, as we work with international companies to promote technology developed at UNMC.

On Friday, Feb. 15, we welcomed our Japanese guests at our office. The UNeMed staff prepared a stimulating schedule highlighting different aspects of technology transfer and a tour of research facilities on campus. “We enjoyed viewing the excellent facilities and discussing with many researchers in the university,” Mr. Kimura said in an email.

Visitors from japanese CompaniesWe exchanged business cards and courtesies, and I had the opportunity to practice my shamefully rusty Japanese. Once our guests settled down, Dr. Dixon described how UNeMed fosters innovation and promotes UNMC technologies with industry collaborations. He was excited to host individuals from two prestigious Japanese companies.

“It’s a great opportunity for us to get more detailed information about global pharmaceutical companies and have an opportunity to expose them to the great research that’s going on at UNMC,” Dr. Dixon said. “I hope we are able to visit their companies in the near future.”

Next, the Japanese visitors presented overviews of their companies and explained their individual roles.

Mr. Kimura works in the Research and Development Department of Kiowa Medex, a member of Kyowa Hakko Kirin group. Kiowa Medex supplies advanced healthcare in vitro diagnostics and equipment. Mr. Kimura was interested in meeting people who worked in sales and marketing of biotech-related products. Kyowa KirinHis area of interest is biomarkers and test kits, as well as biotech/medical in general.

Mr. Toya works in the Legal Affairs Department of Kobayashi Pharmaceutical, which manufactures and sells OTC pharmaceuticals, oral hygiene products, deodorizing air fresheners, sanitary, and other products. Kobayashi PharmaceuticalToya was interested in the legal aspects of the technology transfer process.

The group then discussed various aspects of technology transfer including, invention receipt, intellectual property, marketing, and licensing. UNeMed’s licensing team presented insights into their responsibilities and roles at UNeMed and some of the projects we are working on. Mr. Kimura actively participated in the discussion and was interested in the aspects of licensing and marketing different technologies. There was an emphasis on establishing collaborations with industry and how individuals within companies are essential to the success of technology transfer at the university.

Qian, a licensing associate who also obtained her PhD at UNMC, and I volunteered to provide a tour of several research facilities on campus. Our Japanese guests had the opportunity to visit the cell analysis and flow cytometry core, the confocal microscopy core, the proteomics core, the biosafety level 3 research facilities, and a research lab. This was the first time Mr. Toya had visited a research laboratory. “I had never visited Research facility such as Medical Center, and I learned many things,” Mr. Toya noted in an email.

Building relationships is important in technology transfer and these types of visits serve as networking events. Visits to our office and research labs help place our university and its technologies on the map of these global companies.

“When you would come to Japan, please let me know and visit my company,” Mr. Kimura reminded us in an email.

UNeMed is looking forward to hosting future IPD trainees and other biotech professionals to foster mutually beneficial relationships for all of those that participate.

About the Author

Agnes Picture
Agnes Lenagh, PhD

Agnes is currently a Licensing Specialist at UNeMed. She is a scientist by training, a free thinker by design, and a bohemian soul by nature. Agnes is part of a team that promotes innovation to make the world a better place. She is working to ensure that scientific and technological developments are accessible to the world. She is also committed to pursuing the passions that inspire her while taking non-conventional approaches to accomplish a meaningful life. @SilverAntigen

Contact Agnes: agnes.lenagh@unmc.edu

Read article

What you need to know about royalty distribution

Comments Off on What you need to know about royalty distribution Blog

by Agnes Lenagh, UNeMed | Feb. 15, 2013

Professor at workAs a licensing associate at UNeMed, it’s my job to get industry partners interested in UNMC technologies. On any given day, I will be walking across campus to chat with faculty about their research and discuss any inventions or research tools they may have that possess commercial potential.

A typical conversation with a UNMC professor might provide details about an exciting new mouse model they created and is gaining popularity among researchers of a particular disease. I then help license the new mouse model to a pharmaceutical company that develops drugs for that specific disease. A license agreement allows the company to use the mouse model to test the efficacy of new drug candidates.

The best part is professors would not only share their knowledge and resources, but could also earn royalties because of the license.

Researchers get excited about the prospects of a licensing agreement, but their excitement is often tempered by their confusion about royalties. At first their eyes light up when they see the licensing revenue numbers, and smirk as they ask about their portion of the proceeds. Smirks soon twist into frowns as they try their best to grasp royalty distribution concepts.

QuestionComprehending royalty distribution policies can be difficult unless you have a law degree or experience in the field. Prior to joining UNeMed, I was oblivious to the rules and regulations regarding the handling of technology licensing revenue. Licensing revenue and its subsequent distribution can be particularly complicated in some cases, and most universities have a small army of licensing representatives and committee members to negotiate these deals and distribute the incoming revenue. But complications are normally worth the trouble for the income they help generate. In this article, we’ll take a look at licensing revenue and how it is distributed by the university.

Types of Licensing Revenue

UNeMed manages the technology portfolio for UNMC and also negotiates contracts and license agreements with industry partners interested in technologies and research tools. Payments made to the inventors represent their share of royalty payments from licensees to UNeMed. The particular royalty distribution to the inventor will depend on the specifications of the license, including the amount of incoming royalties, and how the licensee pays (quarterly, annually, or otherwise), the amount of costs invested in the patenting, and if there are any co-inventors.

First, we need to distinguish between different types of payment under a license agreement:

  • Licensing Fee: A one-time payment for the granting of rights to a licensee.
  • Milestone: A payment made by a licensee when the licensed technology is advanced to a specified stage of development.
  • Percent Royalty: A regular payment typically based on a percentage of net sales. Percentages vary with the stage of the technology. For example, royalty percentages might be about 2-3 percent for a technology at pre-clinical testing; 3-4 percent if in clinical trials; 3-5 percent for antibodies; 5-7 percent for an FDA approved drug, and a drug with market share may earn 8-10 percent.
  • Guaranteed Minimum Payment: The minimum amount of royalty payments that the university will receive over a specified time period.

While inventing a commercially valuable technology could make a fortune for the inventors, most inventions do not. It all depends on the innovative nature of the technology; its stage of development; the market potential; and negotiated licensing terms.

Distributing Revenue at UNMC

Royalty DistributionWhereas research institutions may have different distribution percentages, each has a policy that dictates the distribution of revenues associated with technology license agreements. UNeMed is also responsible for managing the expenses and revenues associated with UNMC technology agreements.

The UNMC Royalty and Equity Distribution Policy (7001) states that:

First, the University is reimbursed for all costs associated with protecting, maintaining, defending and commercializing the technology.

Patents are very expensive at $10,000 to $20,000 just to draft and file. The University makes the upfront investment and takes the risk, and sometimes provides assistance with prototyping or software services.

After costs are recouped, revenue is dispersed as follows:

  1. Inventors receive 33 percent
  2. UNeMed receives 15 percent to help cover overhead and operating costs that include things like salary, wages, equipment and other important expenses
  3. Colleges, departments, units and institutes that contributed to the licensed invention all receive a proportional part of a fund created with 10 percent of the first $2 million of royalties, 20 percent for revue greater than $2 million
  4. The remainder proceeds then go “to the UNMC Chancellor’s office to enhance the services of the technology development office to support services to faculty in the filing of disclosure, protection of intellectual property and the marketing, licensing and commercialization of technologies. A portion of these funds may be used for grants to develop prototypes and conduct additional research to facilitate commercialization of technologies.”

If there is more than one inventor or technology on the license, a Royalty Sharing Agreement (RSA) is signed by each inventor. The RSA outlines how any net revenue will be distributed. Without an RSA, the revenue is distributed equally.

Proceeds are used on a case-by-case basis to promote innovation and foster education on campus. Funding is available for specific research projects that may develop existing and future intellectual property with commercial potential.

Getting the money

Inventors often ask us how much money will they make and when. Earning money is an attractive motivation for inventing and licensing a technology, but the actual payment amount can’t be predicted. The royalty distribution to the inventor depends not only on the licensing agreement, but also the merits and commercial success of the invention.

royaltyOnce UNeMed receives the payment from the licensee, they first cover all costs incurred that are associated with the technology. Next, the inventor’s share is one third of the remaining revenue. The royalty payment check will arrive by mail to the inventor’s house and is subject to taxation as income.

Most inventors don’t become overnight celebrities nor retire on technology licensing royalties, but it is possible that the world will be a better place because of their invention. Royalties are an attractive incentive to promote innovation and it doesn’t hurt to have a few extra dollars to buy that state of the art pipette set for the lab.

Join us next week when we discuss more about Patentable Inventions.

About the Author

Agnes Picture
Agnes Lenagh, PhD

Agnes is currently a Licensing Specialist at UNeMed. She is a scientist by training, a free thinker by design, and a bohemian soul by nature. Agnes is part of a team that promotes innovation to make the world a better place. She is working to ensure that scientific and technological developments are accessible to the world. She is also committed to pursuing the passions that inspire her while taking non-conventional approaches to accomplish a meaningful life. @SilverAntigen

Contact Agnes: agnes.lenagh@unmc.edu

Read article

Commercialize your technology: How to bring a product to market

Comments Off on Commercialize your technology: How to bring a product to market News

Dr. Gary MadsenOMAHA, Neb. (Feb. 13, 2013)—“Commercialize your technology: How to bring a product to market” is the title of the second talk given by Dr. Gary Madsen since joining UNeMed as Entrepreneur in Residence last June. His first talk, “What is an EIR and how can he help you” was given at this year’s Innovation Week and introduced the focus and goals of his new position.

The new talk, scheduled for Monday, February 18, is more of a “how to” guide for faculty members to follow when commercializing their technology through a newly formed company.

Before jumping headfirst into a new commercial venture, Dr. Madsen discusses some factors to consider in favor of and against starting a new company. He then methodically takes each step of the new company’s pathway and discusses the most important aspects for founders to focus on.

The seven steps in the process he describes include everything from obtaining a license to implementing a marketing team and sales channel, and everything in between. The talk will be informal and open to lots of questions and discussion.

Read article

Patent-eligible subject matter: Could you patent a man-made life form?

Comments Off on Patent-eligible subject matter: Could you patent a man-made life form? Blog

by Bill Hadley, UNeMed | Feb. 5, 2013

bacteriaInvention disclosures are the lifeblood of university technology transfer offices. Without an influx of quality inventions from faculty, graduate students, and other university employees, these offices would cease to exist. Unfortunately, what qualifies as a patentable invention – especially in the life sciences – can be difficult to understand. Indeed, it is my experience that many university research centers sit on a wealth of intellectual property that has never been disclosed for the simple reason that its creators never realized that they could obtain a patent on the results of their work.

To illustrate the complexity of this issue, take the curious case of Ananda Mohan Chakrabarty. In 1971, Chakrabarty, then working for General Electric, developed bacteria capable of metabolizing crude oil. The bacteria quickly garnered widespread acclaim for its ability to mitigate the damage caused by oil spills. Noting that no naturally-occurring bacteria possessed this property, Chakrabarty and GE applied for a patent.

Consider that for a moment. In effect, Chakrabarty had created a new life form that had never existed in nature, and had the audacity to attempt to patent – monopolize! – the rights to that lifeform.

While the ethical and political ramifications of Chakrabarty’s patent application are staggering, the pertinent question for our purpose is much simpler: “Can you even patent that?” This is, hopefully, the same question many researchers have about their own research. So, without further ado, let’s take a closer look at the types of inventions that are eligible subject matter for patent protection.

The Patent Act of 1952 lists four categories of patentable subject matter for a utility patent:

  • Processes
  • Machines
  • Manufactures, or “Articles of Manufacture”­
  • Compositions of Matter

 

Additionally, any improvement to an existing invention in one of these fields is eligible for patent protection. These terms are ambiguous so let’s take a closer look at each to sort them out.

Processes

planningThe first thing to note here is the term Processes also includes methods.  Process patents can become complex when discussing things like software patents or business method patents. But for most purposes, a process is generally thought to be intended to cover things like manufacturing processes which is a series of steps to make something.

A method generally refers to a specified way of using something.

Thus, a description of a series of steps to cure rubber might be a process, while a method might comprise the steps of a specified administration of a therapeutic agent to treat a condition.

Machine

A Machine can be thought of as a concrete thing, consisting of parts, or of certain devices and combinations of devicesThis includes mechanical devices, or combinations of mechanical powers and devices to perform some function and produce a certain effect or result.  So, a machine may be something like a carburetor, a laser, or a photocopier – devices that autonomously perform a function utilizing a system, or systems, of mechanical devices.

Manufactures

Manufactures, also called Articles of Manufacture, are tangible items or commodities, such as ceramics, alloys, or simple tools.

Patentable Subject Matter

PillsA U.S. patent court decision defined Compositions of Matter as “all compositions of two or more substances and all composite articles, whether they be the results of chemical union, or of mechanical mixture, or whether they be gases, fluids, powders, or solids.” Put another way, a composition of matter is, essentially, any tangible “thing” which is formed by the combination of two or more components, and which possesses properties belonging to neither parent component in each parent component’s individual capacity.

Inventions Not Eligible for Patent Protection

Interestingly, just as there are certain statutorily defined categories of patentable subject matter, certain types of inventions are excluded from patent eligibility.  These excluded inventions include:

 

A Patent for Chakrabarty’s Invention

The controversy over the patentability of Chakrabarty’s organism reached the Supreme Court in 1980. The court first noted that there was no obvious congressional intent to disavow living organisms as patentable subject matter, noting that “Congress thus recognized that the relevant distinction was not between living and inanimate things, but between products of nature, whether living or not, and human-made inventions…”.

Thereafter, the only remaining issue for the court to determine was whether Chakrabarty’s organism fell into one of the four specified categories. This, in turn, boiled down to whether the organism was an article of manufacture, a composition of matter, or neither. In evaluating this question, the court reasoned that:

[Chakrabarty’s] claim is not to a hitherto unknown natural phenomenon, but a non-naturally occurring manufacture or composition of matter – a product of human ingenuity ‘having a distinctive name, character and use’…[Chakrabarty] has produced a new bacterium with markedly different characteristics from any found in nature and one having the potential for significant utility.  His discovery is not nature’s handiwork, but his own; accordingly it is patentable subject matter under §101.

The court does not, of course, specify which category Chakrabarty’s organism falls into – that would be entirely too helpful.

So, if the Supreme Court of the United States is unable to accurately figure out how to classify these things, what is a simple researcher to do?  My advice?

Call UNeMed.

If you have any questions or comments, please do not hesitate to contact the author or leave a comment below.

Join us next week when we discuss the Royalty Distribution.

About the Author

Bill Picture
Bill Hadley, JD

Bill has ample experience handling evaluation, development, marketing, and licensing for medical device, software, and telemedicine-based invention disclosures. He received a B.S. in Chemistry from the Colorado School of Mines and a J.D. from the Creighton University School of Law.

Contact Bill: whadley14@gmail.com

Read article

Six Seconds in Dallas: Fair Use and the Kennedy Assassination

Comments Off on Six Seconds in Dallas: Fair Use and the Kennedy Assassination Blog

by Bill Hadley, UNeMed | Jan. 9, 2013

Kennedy car

President Kennedy, his wife Jacqueline, and Texas Governor John Connally in the presidential limousine, minutes before Kennedy was assassinated on Nov. 22, 1963.

On November 22, 1963, at precisely 12:30 pm, shots rang out from the Texas School Book Depository overlooking Dealey Plaza in Dallas, Texas.  The shots tore into the motorcade that traveled through the plaza, wounding Texas governor John Connally,  bystander James Tague, and killing John F. Kennedy, the 35th President of the United States.  Also present that day was Abraham Zapruder, a russian immigrant who had, on a whim, decided to film the motorcade as it passed through Dealey Plaza.  While there were many photographers present, in a bizarre stroke of fortune (or misfortune), Zapruder was one of the few people actually capturing the procession on film –  and one of the fewer still who were capturing film from a vantage point that provided an unimpeded view of the presidential motorcade as the bullets ripped through it.

All told, the “Zapruder Film” comprises 26.6 seconds (486 frames) of footage documenting the event. Recognizing the value of the footage, Zapruder promptly sold the original film to Life Magazine for $150,000 (just over $1.1 million today). Three years later, Josiah Thompson, a former employee of Life, decided to publish his own account of the tragedy in his book Six Seconds in Dallas.  Unable to receive Life’s permission to use frames from the Zapruder Film in his recounting of the events, Thompson hired an artist to re-create the relevant frames from the film in the form of charcoal sketches, which were subsequently included in the book for analysis.

Shortly thereafter, Life sued Thompson for infringing its copyright in the Zapruder Film and, inherently, the still frames that make up the film.  Among other defenses, Thompson claimed that his re-creation of the frames was permissible under the Fair Use Doctrine – a principle that permits copyright infringement in certain circumstances (note: at this time Fair Use was a common law principle – today it is formally codified in the Copyright Act).  In 1968, the Federal District Court for the Southern District of New York heard the case and ruled in favor of Thompson (Time, Inc. v. Bernard Geis Assocs., 293 F. Supp. 130 (S.D.N.Y 1968).

If you’re scratching your head over this one, don’t feel bad.  Ostensibly, this is a textbook case of copyright infringement: after all, Thompson duplicated a creative work – the Zapruder Film/frames – to which he had no legal claim, without the permission of the lawful owner, and published the duplicate images for his own financial benefit.  So how on earth did the court find this permissible?  To understand, it’s imperative that one is familiar with the Fair Use defense – perhaps the most ambiguous, frustrating, non-sensical, and necessary, limitation on the scope of copyright protection.

The Fair Use Defense and the Copyright Act of 1976

Fair use (also called “fair dealing” in certain foreign jurisdictions) is an affirmative defense to a charge of copyright infringement that permits limited use of a copyrighted work without permission from the copyright holder.  Typical fair uses of a copyrighted work are for purposes such as criticism, commentary, scholarship, and parody.  At its core, fair use is representative of the balance inherent in all intellectual property schemes; in this case, it is recognized that, in some circumstances, public policy dictates that limited use of copyrighted material should be encouraged, despite the potential negative implications on the incentives offered by §106 of the copyright act.

Note that fair use is an affirmative defense to a claim of copyright infringement.  That is, even if a copyright holder can establish that a defendant infringed their copyright, if the defendant can show its use of the protected work is permitted under the fair use provision of the copyright act, the defendant will not be liable for copyright infringement.  To help determine if a specific use of copyrighted material is permitted as a fair use, Congress has implemented a four-factor test in 17 U.S.C. § 107 to weigh the equity – fairness – of the use.

17 U.S.C. § 107 states, in relevant part:

Notwithstanding the provisions of §106 and §106(a), the fair use of a copyrighted work, including such use by reproduction in copies or phonorecords or by any other means specified by that section, for purposes such as criticism, comment, news reporting, teaching (including multiple copies for classroom use), scholarship, or research, is not an infringement of copyright.  In determining whether the use made of a work in any particular case is a fair use the factors to be considered shall include –

1.   The purpose and character of the use, including whether such use is of a commercial nature or is for nonprofit educational purposes;

2.   The nature of the copyrighted work;

3.   The amount and substantiality of the portion used in relation to the copyrighted work as a whole; and

4.   The effect of the use upon the potential market for, or value of, the copyrighted work.

Note that this is a factors test:  that is, a court will consider each factor independently in order to weigh the overall equity in permitting the infringing use.  Due to the subjective nature of each factor, along with their high degree of sensitivity to specific facts,  it would take pages to summarize the way courts have come out on fair use analyses.  I will not go into that much depth here, but here’s a little taste of what courts tend to look at when considering each factor.

Purpose and Character of the Use

Cartoon

Courtesy of Courtoons.com.

Arguably the most important factor in the fair use analysis is the purpose and character of the use of the work.  In evaluating the use, “transformative” uses are more likely to weigh in favor of the would-be fair user while uses that are “derivative” are more likely to weigh against a fair use finding.  Generally speaking, a work is transformative if it includes independent creativity by the would-be fair user, such as in a piece of criticism (where a copyrighted passage might be reproduced for purposes of analysis in the criticism) or a parody (where copyrighted material might be reproduced in order to comment on it).

For an interesting (and awkward…) discussion of the importance of this principle, check out Campbell v. Acuff-Rose, Music Inc., 510 U.S. 569 (1994), where 2 Live Crew’s  parodic sampling of Roy Orbison’s Oh, Pretty Woman was determined to be a sufficiently transformative fair use of the original work.

Nature of the Copyrighted Work

Arguably the least important factor in the fair use analysis, here courts look to evaluate the degree of creativity of the copyrighted work.  As such, fictional works generally weigh in favor of the copyright holder while non-fiction works are more likely to favor the would-be fair user (as Life Magazine found out…but I am getting ahead of myself).

Amount and Substantiality of Use

In evaluating this factor, courts look at both ‘how much’ and ‘what’ the would-be fair user has taken from the copyrighted work.  Courts have run the gamut here, finding for a fair use defense even when a user has liberated all of a copyrighted work (see e.g. Kelly v. Arriba Soft Corporation, 280 F.3d 934 (9th Cir. 2002)) and against a fair use defense when the user took only a small piece of the copyrighted work (Harper & Row Publishers Inc. v. Nation Enterprises, 471 U.S. 539 (1985).

Overall, there are two primary considerations at play here.  First, did the would-be fair user take as little of the copyrighted work as necessary to complete its own creative work?  If so, it favors a finding of fair use.   Secondly, did what was taken of the copyrighted work make up the “heart” (e.g. most powerful or interesting passages, the definitive quality of the copyrighted work, etc.) of it?  If yes, courts tend to disfavor a fair use finding.

Effect of Use on Copyright Value

The final factor in the fair use analysis considers the effect the would-be fair use has on the market value of the original copyrighted work.  If the fair use harms the market value of the original work, courts tend to disfavor the fair use, while if it has no impact – or increases – the value of the original, courts will generally favor a fair use determination.  Note that while the later decided Campbell case (above) describes the primacy of the “purpose and character” of the use as a factor, earlier cases, such as Harper & Row, assert the primacy of the “Effect of Use” factor as the most important consideration.

 Application of the Fair Use Defense

fair useReliance upon the fair use defense is problematic. Not only can evaluations of the different factors vary widely amongst different courts, but judges are given little guidance as to how the factors should be weighed against each other.  What, for example, is a judge to do with a highly transformative parody, when the underlying copyrighted work was very creative, was copied in its entirety, and the parody significantly diminishes the commercial value of the underlying work?  What about a work that is copied in its entirety, for purely commercial benefit by the would-be fair user, but where the work is minimally creative and the value for the underlying work is not harmed?

Unfortunately, given the subjective nature of the factors involved (e.g. How transformative is “enough”? What is the “heart” of the work?  How creative, exactly, was the underlying work really?) and the factors’ sensitivity to specific fact patterns, fair use case law has a broad spectrum of results and is not very helpful, on the whole, either.

Ironically, the difficulties with the fair use defense were specifically addressed (intended?) by Congress as far back as 1967, when, in an impressively prescient analysis, the House Judiciary Committee noted that:

Although the courts have considered and ruled upon the fair use doctrine over and over again, no real definition of the concept has ever emerged.  Indeed, since the doctrine is an equitable rule of reason, no generally applicable definition is possible, and each case raising the question must be decided on its own facts…the endless variety of situations and combinations of circumstances that can arise in particular cases precludes the formulation of exact rules in the statute. 

Eventually the fair use doctrine was codified in the Copyright Act of 1976 (as 17 U.S.C. §107), but the concerns of House Judiciary Committee persist.  As such, there will always be a degree of uncertainty whenever a fair use defense is in play.

Fair Use and the Zapruder Film

So how did the court find in favor of Thompson based on his fair use claim?  You can find the court’s analysis in para. 131-4 of Time, Inc. v. Bernard Geis Assocs., but the following passage stands out in terms of illuminating the court’s thought process:

There is a public interest in having the fullest information available on the murder of President Kennedy. Thompson did serious work on the subject and has a theory entitled to public consideration. While doubtless the theory could be explained with [other non-infringing representations], the explanation actually made in the Book with copies is easier to understand. The Book is not bought because it contained the Zapruder Pictures; the Book is bought because of the theory of Thompson and its explanation, supported by Zapruder pictures.

In other words, the public’s interest in Thompson’s analysis of the work, enabled by his infringement of the frames of the Zapruder Film, outweighed Life’s interest in the copyright.  Given Thompson’s financial interest in the infringement and the overall bad faith he showed in intentionally copying the frames, this certainly is an interesting outcome for an equitable doctrine – but it goes to show how perplexing the fair use doctrine can be.

So, given everything discussed above, the take-home message is this:  when utilizing someone else’s copyrighted material, try to obtain permission first.  If you do not, are sued, and are subsequently forced to assert a fair use defense, the only person who can be confident of a win will be your attorney.

If you have any questions or comments, please do not hesitate to contact the author or leave a comment below.

Join us next week when we discuss the implications of technology transfer.

About the Author

Bill Picture
Bill Hadley, JD

Bill is a licensing associate at UNeMed, where he handles evaluation, development, marketing, and licensing for medical device, software, and telemedicine-based invention disclosures. He received a B.S. in Chemistry from the Colorado School of Mines and a J.D. from the Creighton University School of Law. Bill is currently in training for next fall’s intramural volleyball league, where he has personally guaranteed at least one victory for the mighty UNeMed Volley Llamas.

Contact Bill: Bill.Hadley@unmc.edu

Read article

The importance of technology transfer

Comments (3) Blog

by Agnes Lenagh, UNeMed | Dec. 18, 2012

domino effect of booksContrary to popular belief, publishing your research will not guarantee that someone will notice your discovery and continue developing it into a tangible product that will reach the end user. As I previously mentioned, technologies first need to be developed and that is achieved through collaborations with industrial partners. For example, once a lead compound is identified it must go through a drug development process that includes pre-clinical research, development, and clinical trials. Additionally, drug development is focused on addressing the regulatory requirements of regulatory authorities, such as the FDA and later on for marketing approval. Overall, the process can be quite expensive and may exceed $100 million dollars per drug compound.

How Does Technology Transfer Occur?

authorTechnology is typically transferred through a license agreement in which the university retains ownership of the intellectual property, while the industrial partner obtains conditional rights to use and develop a technology. Before the technology transfer can take place, inventors must define and disclose the nature of their invention to the institution’s technology transfer office. New inventions are evaluated by technology licensing experts, who determine the intellectual property position and potential market for the technology. The technology transfer office will not be able to proceed with the invention if there is no intellectual property available, no value to industry or appropriate competitiveness in the market. On the other hand, inventions with an appropriate intellectual property and market position are given the green light and intellectual property rights are pursued. An invention management and commercialization strategy can begin once the intellectual property rights are established.

Technology transfer requires a proactive approach that combines engaging researchers, promoting the technology, and encouraging potential industrial partners to use the technology.

AgreementThe end goal of the commercialization strategy is to establish a commercial relationship with another party (e.g., employment, a sale or license), and negotiating a contract (e.g., compensation). A license is a contract between a licensor (e.g., the holder of a patent) and a licensee (e.g., an industry partner) that includes a number of conditions that the third party must satisfy. The licensee may be an established company or a new business start-up (that may be founded by the researcher).

The technology transfer office may grant nonexclusive, partially exclusive, or exclusive licenses. Multiple nonexclusive licenses may be granted to several companies to offer better opportunities to broaden the use of an invention across different fields. As mentioned above, the industry partner must satisfy a number of conditions which may include creating a satisfactory development or marketing plan, supplying information about the company’s ability to implement the plan, develop and commercialize the invention within a specified period of time, and making financial payments to the university. These payments are distributed to the inventors and shared within the institution to provide support for additional research, education, and participation in technology transfer activities.

Why is Technology Transfer important?

Technology transfer helps develop early stage intellectual property into tools for direct use by the research community, or into bases for new platforms, products, or services to be made into products for public use. Successful collaborations are formed between researchers across different universities or industries in order to advance the knowledge in a particular field or to further develop a technology. These collaborations may result in licensing or sponsored research opportunities that benefit both partners. In addition, technology transfer ensures that the interests and rights of the university in the intellectual property are protected. The university is able to retain the intellectual property rights of the technology and issue a license for the conditional use of the technology.

PillsSuccessful transfer and development of the technology helps promote the research institution and its commercial partners. The university obtains recognition and increases its reputation for their research and innovation potential. Industry partners can also reduce the costs incurred during their research and development stage by licensing technology from a university. Another benefit for the university involves using the licensing revenue to support further research and education at the institution. Universities protect their investments in research by patenting new technologies, which gives them an opportunity to reach the stream of commerce. The university’s investments in the technology help stimulate local economic development. The ultimate beneficiary of technology transfer is the public, who benefits from both the products that reach the market and the jobs resulting from the development, manufacturing, and sale of products.

I hope that this overview helped illustrate the field of research commercialization. Technology transfer works to complement academic research by pushing innovations out the lab door and into the hands of industry partners who will develop them into products for the benefit of the general public. Remember, if you have a research discovery that helps solve a significant problem, if the idea is innovative and unpublished, or if you believe you have discovered something unique with commercial potential or research value, don’t hesitate to consult with your technology transfer office. Here at UNeMed, we are always eager to help the University of Nebraska Medical Center faculty, staff, and students with any possible inventions they may have.

Contact us via email to report a research tool, or to discuss possible inventions. If you have any questions or comments, please do not hesitate to contact the authors or leave a comment below.For more information, you may also refer to our Inventor’s Handbook.

Read article

Technology transfer 101: Defining research commercialization

Comments (1) Blog

by Agnes Lenagh, UNeMed | Dec. 11, 2012

authorAs a graduate research assistant I constantly heard about the importance of performing valuable research that will someday help develop a diagnostic, prevention, or treatment for a disease. Typically, researchers publish their work to announce their discoveries to sustain and further their career and with the hope that someone will notice and use their idea to improve public health. Unfortunately, most ideas and technologies that stem from research activities are at an early stage of development. Research at academic institutions is geared to gaining better understanding in the field of study and while discoveries have great scientific significance, they might not have immediate commercial value because they lack proof-of-concept studies, a prototype, or a specific product to be commercialized. Before a diagnostic or therapeutic reaches the end user, it will be further developed in compliance to strict regulation and eventually undergo clinical trials. Most research institutions don’t have the means to cover the expensive and often lengthy development process and clinical trials. For this reason, universities partner with pharmaceutical and biotech companies.

Enter Research Commercialization and Technology Transfer

AgreementResearch commercialization allows technology created during research activities to be further developed into marketable products for the benefit of the public. This is achieved through technology transfer, which is the process by which technology, skills, or knowledge developed during research activities at the research institution are applied and used in another place. Technology transfer often refers to transferring a technology between a research laboratory and a commercial partner, including industry, academia, and state and local governments.

The technology transfer process typically involves:

  • Identifying new technologies stemming from research activities
  • Protecting the intellectual property of technologies through patents and copyrights
  • Forming marketing strategies to further develop and commercialize the technology to existing private sector companies or newly created startup companies

The federal government has actively supported and encouraged technology transfer with respect to technologies generated with federal funds. All researchers in federally funded laboratories are required to consider technology transfer an individual responsibility and new discoveries and technologies must be reported to the funding agency.

Investigators are obligated to report any inventions resulting from research activities to the federal funding agency.

LawA series of laws have been established to increase the technology transfer between federally-funded laboratories and nonfederal organizations while providing external entities with a means to access new technologies. Of these laws, the Bayh-Dole Act is credited for stimulating interest in technology transfer, as well as increasing research commercialization, educational opportunities, and economic development in the United States.

The Bayh-Dole Act of 1980 (P.L. 96-517) established boundaries regarding patents and licenses for federally-funded research and development. This Act allows universities, small businesses, and non-profit organizations to have ownership rights to inventions resulting from federally-funded research programs. Major provisions of the Bayh-Dole Act include the following:

  • Make efforts to protect (file patents) and commercialize (promote the use) innovations they elect to own
  • Submit progress reports to the funding agency
  • Give preference to small businesses that demonstrate sufficient capability of bringing the invention to practical application
  • Sharing any resulting revenues with the inventors
  • The government retains march-in rights and a non-exclusive license to practice the patented invention throughout the world

Why does Intellectual Property Matter?

IDEATechnology is typically transferred through a license agreement in which the university retains ownership of the intellectual property created during research activities, while the industrial partner obtains conditional rights to use and develop a technology.

Intellectual property is regarded as subject matter that can be protected under the laws governing the different forms of intellectual assets. These intellectual assets may include products resulting of the human intellect, including inventions, discoveries, creations, developments, or other forms of expressing an idea. Intellectual property may be protected using patents, copyrights, trademarks, and trade secrets. The rights to an article of intellectual property may be bought, sold, leased, rented, or transferred between parties. Additionally, the transfer of intellectual property rights can affect a product’s marketability.

Intellectual property is an essential component when evaluating an invention’s commercialization potential. A common occurrence among researchers is the desire to make their discoveries known and yet, a publication or presentation will not guarantee that the invention will be developed into a marketable product. On the contrary, patent rights are affected by public disclosures, such as presentations and publications in some form. Because patent laws vary by country, a publicly disclosed invention may have restricted or minimal patent protection outside of the United States. Biotechnology companies are interested in not only helping people but also in generating revenue, and as a consequence, technologies need to have strong intellectual property position.

Kepts safe in secretFor this reason, it is critical that confidentiality is maintained until the intellectual property rights have been secured. For example, let’s analyze a typical situation that could happen to any researcher. A new compound that functions as an antibiotic is discovered in a lab and the researchers confirm the results. They also discover that this compound not only has great efficacy and cures bacterial meningitis in an animal model but it also appears to have low toxicity. While preparing the manuscript for publication, the graduate student in charge or the project realizes that his favorite scientific conference is now accepting abstracts. Wanting to share his discovery with the other researchers in the microbiology field, he submits an abstract and is accepted to present a poster. At the conference, a representative from fictitious MicroPharma observes the results and has a good chat with the student. Several weeks after the conference, the primary investigator receives a call from a MicroPharma business development representative. They are interested in more information about the technology. The call is directed to the technology transfer office, who is very excited to work with both the researchers and MicroPharma. Unfortunately, the staff of the technology transfer office had never heard of the compound. While they proceed with the necessary steps to evaluate and protect the technology, they cannot obtain intellectual property protection outside of the United States. The company hesitates to invest in the technology because they were interested in developing the compound in India, where there is a need for new antibacterial compounds. Once again, public disclosure has created a disadvantage for technology transfer.

The example might have been a bit farfetched but it’s not unrealistic. Sometimes researchers disclose their research ideas and developments after they have presented or published it. Often, the technology is abandoned because of the intellectual property cannot be protected. To ensure that the intellectual property is appropriately protected, researchers are highly encouraged to first disclose their discovery to their institution’s technology transfer office (e.g. UNeMed) before sharing the invention with people outside the university.

Contact us via email to report a research tool, or to discuss possible inventions. If you have any questions or comments, please do not hesitate to contact the authors or leave a comment below.For more information, you may also refer to our Inventor’s Handbook.

Join us next week when we continue our discussion on the importance of technology transfer.

About the Author

Agnes Picture
Agnes Constantino, PhD

Agnes is currently a Licensing Associate with UNeMed. She is working to ensure that scientific and technological developments are accessible to the world and that the world, in turn, understands their implications. She is also committed to pursuing the passions that inspire her while taking non-conventional approaches to accomplish a meaningful life. Follow @SilverAntigen

Contact Agnes: aaconstantino@unmc.edu

Read article

Limitations on Copyright: The First-Sale Doctrine

Comments Off on Limitations on Copyright: The First-Sale Doctrine Blog

by Bill Hadley, UNeMed | Nov. 19, 2012

Textbooks are expensive – really expensive. In fact, according to the U.S. Government Accountability Office, over the past two decades, the price of college textbooks has tripled, averaging around $1,200 a year for most students. Considering most students are on fairly tight budgets, it should come as no surprise, then, that there is a vibrant secondary market for used textbooks, and many students elect to save a healthy amount of money each year buying used books. In fact, this practice is so commonplace that the act of buying a used textbook is seen by most students as more or less a rite of passage in the college experience. Supap Kirtsaeng, however, saw it as an opportunity.

Used booksKirtsaeng, a native of Thailand, came to the U.S. in 1997. While in the U.S., Kirtsaeng attended Cornell University and later received a PhD in mathematics from the University of Southern California. In order to subsidize his college expenses, Kirtsaeng did what many college students do: he sold used textbooks. There was only a small difference – Supap Kirtsaeng (allegedly) made over 1.2 million dollars doing so.

So how did Kirtsaeng pull that off? It’s actually quite simple:  publishers generally charge more for textbooks sold in the U.S. than for those sold abroad. For example, where the market clearing price for a new textbook in the U.S. might be $200, a substantially similar version of the book might only be affordable for the equivalent of $20 to a student in Thailand. Recognizing this, Kirtsaeng’s family members would buy textbooks in Thailand at the reduced cost, ship them to Kirtsaeng, and Kirtsaeng would sell the books in the U.S. at a price undercutting the domestic cost of the textbook.

Catching onto this scheme in 2008, textbook publisher Wiley & Sons sued Kirtsaeng for infringing Wiley’s copyrights in the textbooks. Wiley eventually won the case, but certiorari was granted to Kirtsaeng’s appeal on April 16, 2011. On Monday, October 29, Kirtsaeng v. John Wiley Sons., Inc. was argued before the Supreme Court. The case highlights important aspects of the First Sale Doctrine – the principle which gives purchasers of a copyrighted work the right to sell that copy of the work to another downstream purchaser.

The first sale doctrine is an important limitation on the scope of copyright protection, so in light of having a copyrights case argued in front of our nation’s highest court, this seems as good a time as any to discuss it.

Codification of the First Sale Doctrine

The First Sale Doctrine is codified in U.S. under 17 U.S.C. § 109(a), which states, in relevant part:

Notwithstanding the provisions of §106(3), the owner of a particular copy or phonorecord lawfully made under this title, or any person authorized by such owner, is entitled, without the authority of the copyright owner, to sell or otherwise dispose of the possession of that copy or phonorecord…

Copyright saleIn other words, once a copy of a copyrighted work is purchased from the copyright holder (or otherwise “lawfully made”), the purchaser of that copy becomes the unlimited owner of the distribution rights (under §106(3) of the Copyright Act) in that copy. The purchaser is thereafter permitted to control, exclude, dispose of, transfer, or otherwise distribute the copy as the purchaser sees fit. The first sale doctrine does not give the purchaser a copyright interest in the author’s creative work; it only transfers to the purchaser the right to distribute their interest in the copy of the work.

Issues at Play in Wiley v. Kirtsaeng

In theory, the first sale doctrine is fairly straightforward. Unfortunately, even the simplest legal principles can become startlingly complex in unforeseen circumstances – and that is certainly the case here. There are a variety of difficult issues the court is looking at in Kirtsaeng which will impact the rights enshrined in §109(a). Fortunately, a brief examination of these issues will serve as a good mechanism for understanding the application of the first sale doctrine in practice.

Let’s look at these outstanding issues now:

1.)    Conflict with Import Rights

While §109(a) gives the owner of a lawfully-obtained copy of a copyrighted work the right to freely transfer ownership of that copy, 17 USC §602(a)(1) states that, “Importation into the United States, without the authority of the owner of copyright under this title, of copies or phonorecords of a work that have been acquired outside the United States is an infringement of the exclusive right to distribute copies or phonorecords under §106…”.  In other words, importing of a copyrighted work into the US, without permission from the copyright owner, is considered copyright infringement under §106.

§602 carves out no exceptions for importation of works lawfully owned by an importer under the first sale doctrine; a plain reading of the text §602(a)(1) therefore conflicts with a plain reading of §109(a) when a person imports a copyrighted work which was lawfully obtained in accordance with the first sale doctrine.  Clearly this makes no sense – and this is the primary reason the case has reached Supreme Court. It will be interesting to see how this conflict is resolved in the decision.

2.)    Contractual Restraints on Alienability

Books around the worldEach textbook sold abroad by Wiley was marked, “Authorized for sale in Europe, Asia, Africa, and the Middle East only…The Publisher may recover damages including but not limited to lost profits and attorney’s fees in the event that legal action is required.” Does this restraint reach through a lawful purchase to limit the distribution rights of the purchaser of the textbook?

Generally speaking, United States common law disfavors unreasonable restraints on alienability built into the transfer or sale of property. In fact, the Supreme Court noted that such unreasonable restraints highlight the need for the First Sale Doctrine in the first place (see e.g.  Bobbs-Merrill Co. v. Strauss, 210 U.S. 339 (1908)). On the other hand, recent cases (e.g. the 9th Circuit’s decision in Vernor v. Autodesk, Inc., No. 09-35969, slip op. at 13871-72), have found that a copyrighted work was licensed to a purchaser – as opposed to sold – and that title to the copy of the protected work was not transferred.  Therefore, the first sale doctrine was not implicated and the restraints on alienability in the license were permissible.

While it is not likely that Kirtsaeng’s purchase of the textbooks overseas will be considered a ‘license’ to the textbooks, Vernor highlights an important principle that should be considered whenever the first sale doctrine is implicated:  was title to the copy of the protected work actually transferred?

The First Sale Doctrine as a Policy

As an observer, determining who will prevail at the Supreme Court level is never easy; interestingly, it can be even more difficult to evaluate who we want to win. That is, the policy implications of a Supreme Court ruling are often just as difficult to untangle, if not more so, than the legal ramifications. Compounding the problem is that who we “want” to prevail is based on entirely subjective notions of fairness.

For example, is it fair to students in the U.S. (many of whom are, or will be, in difficult financial situations) that Wiley charges astronomical prices for its books in the US while charging barely above the break-even price for the same product abroad? It may not seem so at first blush, but it is important to remember that one of the hallmarks of intellectual property is that the rights-holder, by virtue of its monopoly power, has the right to sell his protected goods at a price of his choosing. Generally it is wise for the rights holder to choose the price that makes the most economic sense from a profit perspective – but should that include the right to segment the market (e.g. domestically and abroad), and if so, to what extent?

domino effect of booksMoreover, consider the impact of the outcome: if Kirtsaeng wins and legitimate owners of copies of protected works are able to import them freely into the U.S., what will result? Probably not lower domestic textbook prices. Rather than drop prices domestically,  Wiley and other publishers will more likely elect to sell each textbook at the same domestic price worldwide – thus, nullifying the incentive to import. The net effect of this is that domestic text book prices in the U.S. stay the same, while textbooks for students abroad become virtually nonexistent in some markets. Is that fair? On the other hand, if Wiley wins, what does that say about the first sale doctrine as a limitation on the scope of copyright considering the effects of globalization on the modern economy?

Let’s be clear: the Supreme Court is only supposed to rule on the matters of law in front of it, policy implications be damned. In theory, the view of the court is that, if ruling on the law results in bad policy, it is the job of the elected members of Congress to draft a law that reflects a good policy. In practice, however, it is naïve to think that policy matters are not considered by the court. Given that the scope of copyright – a policy – should be given at least some consideration in Kirtsaeng, it will be interesting to see how the court rules.

Cases like Kirtsaeng make it all the way to Supreme Court very rarely and the outcome could set a narrative for the way the court interprets the scope of copyrights for years to come – a particularly compelling topic considering the ambiguity in the copyright law as it pertains to the internet and digital mediums of expression.

If you have any questions or comments, please do not hesitate to contact the author or leave a comment below.

Join us next week when we discuss the implications of technology transfer.

About the Author

Bill Picture
Bill Hadley, JD

Bill is a licensing associate at UNeMed, where he handles evaluation, development, marketing, and licensing for medical device, software, and telemedicine-based invention disclosures. He received a B.S. in Chemistry from the Colorado School of Mines and a J.D. from the Creighton University School of Law. Bill is currently in training for next fall’s intramural volleyball league, where he has personally guaranteed at least one victory for the mighty UNeMed Volley Llamas.

Contact Bill: Bill.Hadley@unmc.edu

Read article

You’re an inventor… now what? Three things you can do with your intellectual property

Comments Off on You’re an inventor… now what? Three things you can do with your intellectual property Blog

by Joe Runge, UNeMed | Nov. 7, 2012

IDEAIntellectual property is an asset which affords its holder the right to exclude others from the use of a particular idea. In this way, an author can prevent a publisher from printing her story or an inventor can stop a company from manufacturing his machine.  Yet it is not always obvious how an intellectual property holder can recover any value from it. Bob Kearns may have invented the intermittent windshield wiper, but his efforts to recoup value from that invention (as recounted in the 2008 movie Flash of Genius) were not at all simple.  As Kearns’ odyssey demonstrates, an inventor may have a great new invention or an improvement to an existing product, but lack the capability to make products that use the invention. To make the most of the asset, creators of intellectual property need to have an end goal in mind: how to convert intellectual property to income.

1. Suing for Patent Infringement

patent infringementAs discussed before, patents give the owner the power to prohibit others from making, using, selling, offering to sell, or importing the protected invention. An obvious method to gain profits from a piece of intellectual property is litigation, through which an intellectual property holder can assert rights and sue infringers. Unfortunately, infringement lawsuits can be enormously expensive, even if they settle early. For patent infringement, the median cost of a lawsuit is over half a million dollars, and requires an infringer that the rights-holder can identify.  Litigation can be enormously lucrative, but it is a very risky way to get a return on intellectual property.

2. Selling a Protected Product Yourself

Another approach to commercialize an invention is to actually make, publish or otherwise produce the idea the intellectual property protects. If there is a good intellectual property position and there is a market for it, the exclusive rights granted by the intellectual property can provide a distinct commercial advantage against competitors. A trademark, for example, gains value only as a business uses that mark to provide goods and services to its customers. That being said, innovators are not always entrepreneurs. Just as some authors are not interested in publishing their own books, some inventors that own intellectual property are not interested in forming their own companies. Moreover, in an age of specialized production and mass media, it can often be very difficult to get the appropriate regulatory approval, start-up capital, good manufacturing process or mass market appeal to profitably exploit intellectual property. As you might imagine, for many innovators, selling products based on their intellectual property may not be a feasible option.

3. IP Licensing

FranchiseA third commercialization approach is for the rights holder to license the intellectual property to a third party. Intellectual property licensing is very complex but it creates an efficient method by which authors, inventors, and other intellectual property holders can get a return for their rights.

Intellectual property licensing is essential for a number of industries, many of which are not technology driven.  Franchising, for example, is built around licensed intellectual property; an entrepreneur can license the right to use the trademarks, know-how, advertising, and other intellectual property of an existing company in order to start a business. In return, the company who licenses their assets may receive a royalty or a fee from the entrepreneur.  Franchising shows the power of licensing intellectual property in the modern economy.  Intangible assets such as know-how, supply chain, methods to find a physical location, and the goodwill associated with a particular brand can be readily packaged and distributed worldwide. It makes possible, for better or worse, the precise application of a successful business model throughout the world.  It also maintains control of the intellectual property with its owners – thereby allowing only the licensee’s conditional use of it.

In technical fields, intellectual property licensing is also powerful. An individual inventor can spend decades perfecting a new process and years seeking a patent to protect it.  She can then identify a company that would benefit from the process and license that company the right to use her patents (while still retaining ownership over them). A patent license further provides the basis for the inventor to provide additional know-how. The license is the transaction whereby the inventor fundamentally transfers the ability to use the technology to the licensee.

There are, however, many considerations an inventor must take into account when licensing his intellectual property. One critical issue is exclusivity: does the company getting the license have only the permission to use the intellectual property or can they exclude others from using the intellectual property? Exclusivity fundamentally changes the nature of the license.  If the inventor of the new process can broadly apply it to a number of competing business, she may be able to non-exclusively license it to each competitor or she could license it to just one competitor exclusively.  Each warrants different terms: an exclusive license needs to capture the whole value of the intellectual property where the rights holder can convey multiple non-exclusive licenses.

AgreementIn addition to exclusivity, another license consideration can be field-limitations.  A franchisee may own the franchise rights for an entire geographical region; such as the license may convey exclusive rights but only for a specific city or state. Similarly, a musician may record a song and license it for many different uses – an advertising company may have exclusive rights to use the song for commercials, a sports team may have exclusive rights to use it during the pre-game show and multiple production companies may have non-exclusive rights to play the song during films and television shows. As with any contract, field-limited licenses need to be specific in defining the field.  Does a license to use a song for television shows include home video reproductions of the show? Does it include web-only broadcasts?  Careful drafting on fields and other definitions of intellectual property licenses is critical for the rights holder to maximize the value of her intellectual property.

Efficient Commercialization of Intellectual Property is Critical

Intellectual property licensing is more than a way for intellectual property holders to obtain value for their patents, copyrights and other intellectual property. It is a means to transfer not only intellectual property, but all of the intangible value that goes with it. In an increasingly specialized marketplace, efficient means to transfer intellectual property and the associated know-how is critical for innovation to benefit the economy.

 

Read article

Innovation Week Continues Today

Comments Off on Innovation Week Continues Today Innovation Week, News

Dr. Gary MadsenYesterday, Dr. Gary Madsen, UNeMed’s Entrepreneur-In-Residence (EIR) discussed his role in the company.

Attendees learned that an EIR takes on different roles depending on the client. UNeMed’s EIR is here to help with business consulting, networking, mentoring, and coaching those who are dwelling or seeking to venture into the entrepreneur realm.

Innovation Week continues with a seminar highlighting the new America Invents Act (AIA).

This federal legislation was signed into law on September 16, 2011 and represents the most significant change to our patent system since 1952.

AIA transformed the U.S. patent system from a “first to invent” to a “first inventor to file” system and this switch will come into effect in March 2013. These and other changes will be discussed by Steven Ritchey, Charles Romano, and Denise Mayfield from Thompson Coburn, LLP.

  • Charles Romano, PhD is a Senior Patent Agent in the firm’s intellectual property area and has over fourteen years of experience in the biotech industry.
  • Steven Ritchey, J.D. is a partner and is involved in the firm’s Intellectual Property practice and is in charge of preparation and prosecution.
  • Denise L. Mayfield, J.D. is a partner in the firm and advises academic institutions, biotechnology firms, and pharmaceutical companies on various areas.

The seminar will be held today at 2:00 PM in DRC-I 1005. Attendees will have the opportunity to interact with the panelists during the seminar.

Read article

Innovation Week Kick-off Event

Comments Off on Innovation Week Kick-off Event Innovation Week, News

Innovation Week

The UNeMed staff greeted over 350 people that stopped by to say hello.

OMAHA, Neb. (Oct. 16, 2012)—Innovation Week officially began yesterday in the Durham Research Center Atrium.

Innovation Week comprises a series of events highlighting UNMC researchers who brought their innovations to the UNeMed office.

Innovation Week

UNMC personnel enjoyed drinks from the ever popular Jo-On-The-Go Espresso and Smoothie Bar and a variety of snacks.

 

 

UNMC personnel that stopped by the kick off event were able to:

  • Enjoy free drinks from the Jo-On-The-Go Espresso and Smoothie Bar;
  • Enjoy samples from a variety of snacks;
  • Grab a free t-shirt featuring this year’s new design; and
  • Select from a variety of neat gifts like water bottles, phone holder, screen cleaners, sticky notes, pens, and more;
  • Register for the iPad giveaway
Innovation Week

UNMC Personnel could select from a variety of gifts.

Visit our Facebook page to see if you or your coworkers were captured by Jack’s mischievous camera.

Innovation Week continues today at 12:30 with a seminar by Dr. Gary Madsen, UNeMed’s own Entrepreneur-In-Residence, who will present “What is an EIR and how can he help you?” in the Durham Research Center Auditorium. Pizza will be provided while supplies last.

See our Schedule of Events to stay up-to-date.

Innovation WeekInnovation Week 1

 

Read article

2012 Research Innovation Week

Comments Off on 2012 Research Innovation Week Innovation Week, News

UNeMed Prepares for the Sixth Annual Innovation Week

OMAHA, Neb. (Oct. 4, 2012)—Following its success over the past five years, UNeMed Corporation announces the return of Innovation Week. Innovation Week 2012will kick off Monday, October 15thwith an event where attendees can meet the UNeMed Staff and grab some cool gifts, while they enjoy snacks and an Espresso or Smoothie. The events will culminate on Thursday, October 18th with the Innovation Awards,a ceremony to honor those individuals who submitted new inventions, obtained patents, and licensed technologies through UNeMed.

Last year, nearly 200 people were exposed to the wide range of services that UNeMed offers. This year we’re gearing up to provide the UNMC research community with a great opportunity to get immersed in the world of technology transfer and commercialization. Innovation week helps raise awareness of how UNeMed can help investigators commercialize their research innovations.

All inventors are recognized during the Innovation Awards for submitting their ideas to the technology transfer office. A special award is given to the most promising new invention. The winning inventor developed an idea that has the most potential to produce a positive impact in healthcare and will receive $10,000 in an unrestricted grant to fund research. A second award will be given to an inventor who is currently working on innovative ideas that have great potential to generate commercial value to the office. This award provides a $25,000 unrestricted research grant.

Additionally, Innovation Week participants can register each time they attend an event to win an iPad. The winner of the iPad will be announced during the Innovation Award Ceremony on October 18th and they must be present to claim their prize.

Make sure you stop by and say hi to the UNeMed staff, we look forward to seeing everyone there!

Schedule of events for Innovation Week

  • October 15th 9 a.m.DRC-I AtriumInnovation Week kicks off in the Durham Research Center Atrium. Come meet the UNeMed staff and grab a free t-shirt and neat gifts while enjoying drinks from Jo-On-The-Go Espresso and Smoothie Bar, as well as snacks. Also, sign up to win an iPad!
  • October 16th 12:30 – 1:30 p.m.DRC-I 1002— Dr. Gary Madsen, Entrepreneur-In-Residence at UNeMed Corp. will discuss what an EIR is and how he can help you. ** Pizza lunch provided while supplies last.
  • October 17th2:00 – 3:00 p.m.DRC-I 1005 — Join Steven Ritchey, Charles Romano, and Denise Mayfield of Thompson Coburn, LLP as they discuss highlights of the America Invents Act.
  • October 18th — 4:00 p.m. ~ — DRC-I 1002 with reception to follow in the Atrium — Innovation Awards Ceremony! ** iPad winner announced at ceremony – Must Be Present to Win!

*** Sign up to win the iPad at the Oct. 15, 16, & 17 events

Read article

Do you recognize how trademarks identify the creator of a good?

Comments Off on Do you recognize how trademarks identify the creator of a good? Blog

by Bill Hadley, UNeMed | Oct. 3, 2012

Trademark definition

When a word or symbol is of a character to be appropriated, as a trademark, it becomes property which a competitor has no right to use, either alone or in connection with matter to which its owner lays no claim, without such owner’s consent.

You get up in the morning and grab a cup of coffee on the way to work. You know what to expect just by looking at the well-known Starbucks siren logo on the cup. You arrive at work, turn on your computer and hear the all-too familiar chime of a Microsoft Windows PC booting up.

For lunch, you stop off at a fast-food restaurant and know that they’re handing you your favorite sandwich at McDonald’s because the Golden Arches haven’t changed much since you first started going there. On your way back home from work, you stop by a shoe store to buy some Nikes. You easily locate a pair by the ‘swoosh’ on its side.

All these product features – the logo, the chime, and the packaging – are trademarks. Trademarks are distinctive signs or indicators used by a provider of a good to identify the provider and distinguish it from its competitors. Thus, a good trademark provides for quick and easy product recognition by consumers.

Trademark law exists only to protect the underlying mark, not the product the mark represents. Thus, trademarks cannot be used to protect an invention (Patents) or literary works, software, or music (Copyrights). Nevertheless, trademarks are an integral part of intellectual property protection.

Today, we’d like to take a few minutes to explain how trademarks work, how they don’t, and how they differ from more well-known protection mechanisms.

What exactly is a Trademark?

Apple iPhone, iPad, and iPod

The Apple brand includes the iPhone, iPad, and iPod

Simply put, trademarks are (nearly) anything that can be used to identify the creator of a good. Because we often attribute the quality of a good to its producer, trademarks are, ipso facto, also signifiers of consumer good will and reputation. By way of illustration, consider: one of the reasons the iPad has been so successful is that, through production of other quality portable electronics such as the iPod and iPhone, consumers attributed the Apple brand with production of quality electronics. Branding electronics with the distinctive Apple logo, therefore, lends an aura of quality – of value – that the product might otherwise lack (at least initially).

The ultimate goal of trademark law is to prevent commercial confusion. Trademarks protect the goodwill of a consumer toward a company (and its reputation) by providing the company a monopoly on the use of the mark attached to its products. Additionally, trademarks protect consumers:  if Apple wasn’t able to exclude other electronics manufacturers – say… Samsung – from placing the apple icon on Samsung electronics, consumers might mistakenly purchase a Samsung electronic device believing it to have the quality of an Apple product. (Please note that this comparison is only for illustrative purposes only – the author has no actual opinion on the value of Samsung and Apple products. He still proudly rocks his Blackberry!)

The Different Categories of Trademarks

Trademarks are classified in levels of ‘distinctiveness’ –  marks which are more “distinctive” (i.e. “fanciful” or “arbitrary”) are afforded more preferential treatment than trademarks that are less so (i.e. “descriptive” or “generic” marks). Trademarks are associated with a category of distinctiveness based on how the mark relates to the product it signifies:  the more related the mark is to the product, the less distinct it is. For an illustration of this principle, take a look at the table below:

Thus, we can see that the context in which the mark is used is of great importance: ‘Apple’, for example, may be a strong arbitrary trademark for a computer, but would probably be a much weaker descriptive or generic mark for an orchard.

Trademark Limitations

While many types of identifying marks are available for trademark protection, there are a few important limitations.  For example, trademarks cannot be “functional” – that is, they cannot perform an action or otherwise contribute to the effectiveness of the product they represent. Thus, the classic contour shape of a Coca-Cola bottle is trademarkable (as it does not contribute to the pleasure derived from drinking a coke), whereas the “wide-mouth” shape of a soft drink can might not be able to be trademarked, because the wider mouth itself contributes to ease of pouring the drink – and thus utility is derived from the design.

Another type of limitation is the ‘Genericization of a Mark’.  It is possible for a once arbitrary or fanciful mark to, over time, become generic due to over-saturation of its use.  For example, ‘Aspirin’ used to be a trademarked name of acetylsalicylic acid owned by Bayer, but due to its colloquial use for “painkiller”, it has been deemed a generic mark in the US.  That is to say, today, if someone wants an ‘Aspirin’, it does not necessarily mean that they want “acetylsalicylic acid produced by Bayer”, it simply means that they want to take a painkiller. Thus, the term ‘Aspirin’ does not serve to identify the producer of a good any longer and thus ceases to be a trademark. Other famous genericized marks include Kleenex for tissues, Xerox for paper copies, Scotch Tape for clear adhesives strips, and maybe even ‘Google’ for internet searches. Understandably, large companies invest substantial resources in policing the use of their marks in hopes of preventing “genericide”.

Trademark Registration

Common law trademark rights may be obtained automatically from use of a mark, alone, in commerce.  Alternatively, a mark may also be registered – so long as there is no identical active mark currently in use – at the USPTO.  Actual use in commerce is not required for a registered mark; instead, a bona fide intent to use the mark in commerce is sufficient.

Without registration, a mark protected by common law is only valid in the region in which the marked goods are actually sold. Registration of a trademark ensures that the mark is valid and can be used nationwide. Runza, for example, has a trademark registered at the USPTO and, therefore, the Runza trademark has effect nationwide. If the mark were not registered, however, it may not be enforceable in states like Colorado, where no Runza franchises are in business.

After a trademark is registered, a company may use the well-known circle R (®) icon with its mark. Marks that are pending registration or are asserting common law rights may use the TM symbol (™). Using the ® icon on a mark that is not registered is illegal.

Why You Should Learn About Trademarks

UNMC Discover

UNMC Discover is a registered trademark owned by Board of Regents of the University of Nebraska.

As a UNMC employee, trademarks will likely only very rarely be of importance to you (UNMC and its employees/students are generally not involved in selling a product or good). Nevertheless, in some cases a familiarity with trademark law might be important. For instance, if you were to spin-out a start-up company around a piece of intellectual property developed here at UNMC, you may want to develop a mark to identify the goods that company intends to sell.

Additionally, you may be involved with work involving the use of other entity’s marks, such as UNMC’s mark, or marks of collaborating institutions or industrial partners. In these circumstances, it is important to be able to recognize their marks and to know when and how that mark may be used.

If you are interested, the University of Nebraska policy on trademarks is set forth in Executive Memorandum No. 20, which states:

(T)he Vice President for Business and Finance and the Principal Business Officer on each of the campus of the University, with the written approval of the Vice President and General Counsel or an attorney on his or her staff, is hereby granted the delegated authority to develop, adopt, and protect University trademarks, trade names, copyrighted designs and other indicia on behalf of the University of Nebraska, its major administrative units and the various administrative subdivisions thereof.

Trademarks related to UNMC may be disclosed to UNeMed via the following form. Supplemental information about trademark law can be found on Harvard’s Berkman Center for Internet & Society website.

If you have any questions or comments, please do not hesitate to contact the authors or leave a comment below.

Join us next week when we discuss the licensing process.

About the Author

Bill Picture
Bill Hadley, JD

Bill is a licensing associate at UNeMed, where he handles evaluation, development, marketing, and licensing for medical device, software, and telemedicine-based invention disclosures. He received a B.S. in Chemistry from the Colorado School of Mines and a J.D. from the Creighton University School of Law. Bill is currently in training for next fall’s intramural volleyball league, where he has personally guaranteed at least one victory for the mighty UNeMed Volley Llamas.

Contact Bill: Bill.Hadley@unmc.edu

About the Author

Dallin Call
Dallin Call, BS

Dallin is a Legal Intern at UNeMed, where he works together with the Contract Specialist to protect, maintain, and enable the contractual rights of UNMC researchers in the intellectual property that they develop. He received a B.S. in Chemical Engineering from the University of Utah and is a student at Creighton University School of Law. Dallin enjoys spending time with his wife and daughter, going on walks, watching movies, reading books together with his family, and playing trivia games. He also likes to play sports, especially basketball.

Contact Dallin: Dallin.Call@unmc.edu

Read article

Dr. Dixon to present Thursday night at Cornstalks

Comments Off on Dr. Dixon to present Thursday night at Cornstalks News

by Michael Stacy, Silicon Prairie News

OMAHA, Neb. (Sept. 25, 2012)—Representatives from Pipeline, a Kansas City, Kan.-based regional entrepreneurial fellowship, are scheduled to present Thursday night at Cornstalks, a monthly forum hosted by the Greater Omaha Chamber of Commerce for people interested in high-growth entrepreneurship.

Thursday’s event gets underway with networking at 6:30 p.m. and features a Pipeline presentation at 7:30. Cornstalks takes place at the Silicon Prairie News office (1111 North 13th St., Suite 208) and is free and open to the public.

Joni Cobb, the founding president and CEO of Pipeline, will talk Thursday. Others tentatively scheduled to present include Pipeline partners Dr. Michael Dixon (UNeMed) and Karen Linder (Nebraska Angels) and current Pipeline innovators Ben Pankonin (Social Assurance) and Blake Lawrence (Hurrdat Social Media).

Pipeline is a year-long program highlighted by intensive, three-day modules each quarter and an Innovator of The Year event in January. The program takes applicants from from Kansas, Missouri and Nebraska and seeks to fill its classes with entrepreneurs that hail from a variety of industries.

Pipeline is accepting applications for its 2013 class until Oct. 29. Thursday’s event is designed to help entrepreneurs interested in applying learn more about the program. People interested in attending Thursday are encouraged to RSVP to Nora Freyman at nfreyman@pipelineentrepreneurs.com.

For more on Pipeline and applications for its 2013 class, see our previous story: “Pipeline opens application process for 2013 entrepreneurial fellowship“.

Read article

How to determine who is an inventor on a patent: Unraveling inventorship vs. authorship

Comments Off on How to determine who is an inventor on a patent: Unraveling inventorship vs. authorship Blog

by Bill Hadley, UNeMed | Sept. 26, 2012

author

Not all authors are necessarily inventors

I recently had a meeting with a faculty member, whom I will call Dr. A, to review an invention disclosure Dr. A had recently made. Shortly after the meeting started, however, Dr. A received a phone call from a colleague (the creatively-named Dr. B) at another university. As I waited for the call to end, I couldn’t help but hear a bit of the discussion.  As it turns out, Dr. B was negotiating with Dr. A to have Dr. B’s name appear on a publication coming out of Dr. A’s lab. Aware that discussions of this nature are common in academia, I didn’t pay this much mind, until, at the end of the conversation, the talk turned to intellectual property.  In return for Dr. A’s agreeing to put Dr. B’s name on a publication coming out of his lab, Dr. A requested that Dr. B include Dr. A on a patent application that was coming out of Dr. B’s work – at which point, I promptly reacted like this. This is a big no-no from a patent perspective and here’s why.

Authorship on a publication is determined by custom; Inventorship on a Patent is determined by law

Autorship

Authorship attribution can even vary between labs.

“Authorship” on a publication is attributed differently among the various academic disciplines and can even vary from institution to institution. In large part, authorship is determined by custom: for an academic publication, a variety of people may be legitimately considered for authorship, including those persons involved in the experimental design, those who performed lab work, wrote or edited the manuscripts, or even contributed their general expertise. Authorship may also be bestowed for financial reasons or professional courtesy to collaborators and mentors.

The rules for inventorship, on the other hand, are determined by law, and violation of these rules can have severe impacts on a resulting patent. In order to show how inventorship of a patent differs from authorship of a publication, let’s take a few minutes to explore the patent law on this oft-overlooked issue.

Inventors are the Original Owners of a Patent

When it comes to patents, inventorship is vitally important.  This is because, under Article I, § 8 of the Constitution, patents are originally owned by their inventors:

The Congress shall have power…to promote the progress of science and the useful arts, by securing for limited times to authors and inventorsthe exclusive rights to their respective writings and discoveries.

This mandate is codified in 35 USC § 101, which limits the persons who can receive a patent to the inventor. (“whosoever invents… may obtain a patent”). Note that § 101 does not prohibit the inventor from subsequently assigning their rights in the patent away (such as in an employment agreement, see e.g. UNMC Board of Regents Policy Nos. 3.10 and 4.4.1). As a procedural step, however,  the identified inventors of a patent must be named the original owners of the patent.

Legal Definition of “Inventor”

InventorBecause inventors are the original owners of their patents, it is imperative to define who, exactly, the inventor of a patent is.

In legal terms, the invention in a patent is defined by its claims – you might expect, then, that the inventor of a patent is defined by the claims as well. This turns out be true, as, to be an inventor of a patented invention, an inventor must have contributed to the conception of the invention and to at least one claim on the issued patent (see e.g. Ethicon Inc. v. United States Surgical Corp., 135 F.3d 1456 (Fed. Cir 1998)).

Moreover, under 35 USC § 116, there may be more than one (i.e. a joint)  inventor of a single patent, so long as each joint inventor individually meets the legal requirement for inventorship described above, and there was at least some concerted effort between the inventors (see e.g. §116; Eli Lilly v. Aradigm Corp., 376 F.3d 1352 (Fed. Cir 2004). Note that there are many problems that can arise in a patent with joint inventors, some of which we have previously noted in our discussion regarding collaborations and their impact on inventions and patents.

Ramifications of Mis-Identified Inventors

If the inventors on a patent are mis-identified, the end-result is that the patent can be invalidated – often costing the inventors thousands of dollars and years of hard work. Fortunately, if the error in identifying the proper parties was made in good faith, these defects can be remedied under either §116 or 35 USC §256. For an excellent summary of actions that can be taken to correct inventorship on a patent, check out this article from Campbell Chiang at Duke University.

The take-home message here is:  don’t use inventorship on a patent application as a commodity, as is sometimes done with authorship on a publication.

This is for two reasons. First, the “agreement” between the collaborators will be found to be invalid if it is ever discovered (which it will be for any valuable patent) – rendering such an “agreement” worthless. Second, if inventorship is found to be invalid due to an intentional act by one valid inventor, courts may construe the bargain as an intentional attempt to defraud the USPTO, thus nullifying the good-faith exceptions to remedying inventorship errors described above.  This could invalidate the patent in its entirety.

From my perspective, full disclosure with your attorney or patent agent is the best policy.  When disclosing an invention to your technology transfer office (or patent attorney), do not simply list the authors of a related publication as inventors. Although all authors may be considered inventors in some circumstances, the inventors of a patent are not necessarily all of the authors of a related publication.

When in doubt, provide your counsel with the names of all the individuals who contributed to the invented work, and let the attorneys decide who fits the bill as inventors.  This may be more work for the attorneys in the short term, but it can pay dividends to the inventors (and investors!) down the road if the patent is ever challenged in court.

If you have any questions or comments, please do not hesitate to contact the author or leave a comment below.

Join us next week when we discuss Trademarks.

About the Author

Bill Picture
Bill Hadley, JD

Bill is a licensing associate at UNeMed, where he handles evaluation, development, marketing, and licensing for medical device, software, and telemedicine-based invention disclosures. He received a B.S. in Chemistry from the Colorado School of Mines and a J.D. from the Creighton University School of Law. Bill is currently in training for next fall’s intramural volleyball league, where he has personally guaranteed at least one victory for the mighty UNeMed Volley Llamas.

Contact Bill: Bill.Hadley@unemed.com

Read article

Five important aspects of copyrights that you should know

Comments (2) Blog

by Bill Hadley, UNeMed | Sept. 17, 2012

60 Years Later: Coming through the rye

In 2009, Fredrik Colting attempted to publish 60 Years Later: Coming Through the Rye, a thinly-veiled sequel to The Catcher in the Rye, by J.D. Salinger.

In 2009, Swedish author Fredrik Colting (under the pen name J.D. California) attempted to publish a  book titled 60 Years Later:  Coming Through the Rye. Unfortunately, Coming Through the Rye, was a thinly-veiled sequel to the 1951 classic, The Catcher in the Rye, by J.D. Salinger.  Both novels are set in New York, feature the same characters (though identified differently – Holden Caulfield is called “Mr. C”, for example), and feature similar events. Salinger sought to prevent Colting from publishing the sequel and sued him for copyright infringement. Salinger eventually won, but Through the Rye illustrates complex issues about the scope of our copyright system.

1. Copyrights promote the progress of science and the useful arts

How far, exactly, does Salinger’s copyright in The Catcher in the Rye extend? Does it allow Salinger to prohibit others from using similar story arcs, characters, or themes? Conversely, Through the Rye can easily be viewed as a simple cash grab – that Colting simply sought to take advantage of the popularity of Catcher in order to “take the easy way out” in writing his own novel. Should this be permitted?  Where do courts draw the line in determining whether Colting was merely “inspired by” Salinger, commenting on Salinger, or whether he was flat-out copying him? Don’t all stories, to some extent, build on their predecessors?

These are not easy questions to answer, and they strike at the heart of the copyright system. Copyrights, along with patents, are explicitly implemented by the Constitution to promote the “progress of science and the useful arts”. But is that really happening here? Some would argue that Salinger’s copyright is inhibiting creative progress by sabotaging Colting’s ability to publish his own work. Others would argue that it is functioning perfectly because Colting’s work is not creative at all:  it simply exploits the creativity of Salinger. Copyrights are necessary, this latter group would argue, to protect the original author’s interest in his creation and to maintain the sanctity of the creative work.

Be under no illusions – I don’t have the space to faithfully examine these (extremely controversial) issues here.  But, by providing the framework for how the copyright system operates, I can hopefully provide a basis for you to reach your own educated conclusion.

2. Works that may be copyrighted

Under 17 USC § 102(a), a copyright may be granted to:

Any original work of authorship fixed in a tangible medium of expression, now known or later developed, from which [the original work of authorship] can be perceived, reproduced, or otherwise communicated, either directly or with the aid of a machine or device.

Using this definition, 17 USC § 102(a) illustrates the types of work that are eligible for copyright protection:

  • Literary works
  • Musical Works
  • Dramatic Works
  • Pantomimes and choreographic works
  • Pictorial, graphic, and structural works
  • Motion pictures
  • Sound recordings
  • Architectural works

 

Pointedly, 17 USC § 102(b) explicitly disclaims ideas, procedures, processes, systems, methods of operation, concepts, principles, or discoveries from copyright protection. In other words, a copyright only extends to the expression of an idea, not to the idea itself. Thus, an author may have a copyright on a novel exploring teenage angst, but the copyright only extends to the expression of teenage angst provided in that novel, not to all novels displaying teenage angst.

3. Exclusive rights are granted by a copyright

Under 17 USC § 106, the owner of a copyright has the exclusive right to do the following with the copyrighted work for the life of the author, plus an additional 70 years:

  • To reproduce the copyrighted works
  • To prepare derivative works
  • To distribute copies of the work
  • To perform the copyrighted work publicly
  • To display the copyrighted work publicly
  • To perform the copyrighted work publicly by means of a digital audio transmission.

 

Unfortunately, the way these exclusive rights work in practice is not at all obvious. In fact, there are far too many nuances to these rights to describe in detail here.  For a more in-depth explanation, check out this article.

4. Unauthorized use leads to copyright infringement

My Sweet Lord

Ronnie Mack sued George Harrison for copyright infringement over Harrison’s 1970 hit “My Sweet Lord”. Compare the works here.

Simply put, a copyright is infringed when there is an unauthorized use of one of the exclusive rights from 17 USC § 106. Sometimes this determination is easy – often it is clear if an unauthorized party is distributing or displaying a copyrighted work. On the other hand, it is much more difficult, in many cases, to determine whether someone is actually reproducing a copyrighted work.

To resolve this issue, courts generally apply some form of the “substantial similarity” test. Determining whether the reproduction right of a copyright has been infringed, however, is actually quite complex, and application of the substantial similarity test is not a settled issue among the circuits. Therefore, for now, suffice to say that infringement of the reproduction right occurs when there has been an unauthorized copying of the material portion of a creative work.

For a comparison of a number of fascinating cases alleging infringement of a musical copyright, I highly recommend checking out the UCLA /Columbia University Music Copyright Infringement Resource.

5. Obtaining a copyright is a piece of cake

A copyright automatically vests in the author upon creation of a copyrighted work in a tangible medium of expression. So, in effect, all that is necessary to obtain a copyright is to complete work that is eligible for a copyright. It is also possible to formally register a copyright. To do so, all that is required is to complete an application form and submit a nominal 35$ fee along with a copy of the copyrighted work to be stored at the Library of Congress. Registering a copyright definitely has a number of important benefits for copyrights with commercial value.

Conclusion

Wikipedia and SOPA

In early 2012, the Congress attempted to pass the “Stop Online Piracy Act” (SOPA) in a desire to curb internet-based copyright infringement. Due to outcry from sources like Wikipedia (shown above), the House Judiciary Committee has postponed consideration of the bill.

Copyright protection extends to original works of authorship which are fixed in a tangible medium of expression.  Furthermore, the copyright only extends to the expression of the idea behind that work of authorship – not the idea itself. Simple, right? Sort of – but unfortunately things become much more complex when applying concepts like Fair Use, Works for Hire, and the First Sale or Merger Doctrines. Moreover, copyrights as applied to software can be even more troublesome, especially when placed in the context of the internet.

The fact of the matter is that copyrights (usually) make a great deal of sense when discussing tangible items like books, artwork, or sheet music (i.e. things that were around when the copyright laws were drafted). They become much more complicated when applied to the newer digital mediums. The Digital Millennium Copyright Act seeks to address some of these issues, but in many cases only makes things more complicated. Hopefully we can discuss this in a subsequent post, but for today I hope this brief summary was useful in providing an overview of this commonly muddled area of the law.

If you have any questions or comments, please do not hesitate to contact the author or leave a comment below.

Join us next week when we discuss inventorship and naming co-inventors.

About the Author

Bill Picture
Bill Hadley, JD

Bill is a licensing associate at UNeMed, where he handles evaluation, development, marketing, and licensing for medical device, software, and telemedicine-based invention disclosures. He received a B.S. in Chemistry from the Colorado School of Mines and a J.D. from the Creighton University School of Law. Bill is currently in training for next fall’s intramural volleyball league, where he has personally guaranteed at least one victory for the mighty UNeMed Volley Llamas.

Contact Bill: Bill.Hadley@unemed.com

Nothing in this post should be construed as legal advice. It has been developed by the UNeMed staff as an educational resource for faculty, staff, students, and other personnel associated with the University of Nebraska Medical Center. While all information contained herein has been thoroughly fact-checked, this site is provided on an “as is” and “as available” basis. Neither UNeMed nor the University of Nebraska Medical Center make any representations or warranties of any kind, express or implied, as to the site’s operation or the information, content or materials included on this site. To the full extent permissible by applicable law, UNeMed and the University of Nebraska Medical Center hereby disclaim all warranties, express or implied, including but not limited to implied warranties of merchantability and fitness for any particular purpose. Neither UNeMed nor the University of Nebraska Medical Center will be liable for any damages of any kind arising from the use of or inability to use this site. You expressly agree that you use this site solely at your own risk.

Read article